About Symbiotec Pharmalab Limited
Data last updated:
Symbiotec Pharmalab Limited is a public limited company based in Mhow, Madhya Pradesh, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 20 September 2002 and has been in existence for over 24 years.
The company is registered with the Registrar of Companies (ROC), Gwalior, under CIN U24232MP2002PLC015293. Its GSTIN is 23AAGCS9311M1Z5 (Madhya Pradesh). The company holds 2 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 544889 and NSE: SYMBIOTEC.
The company has an authorised share capital of ₹30 Cr and a paid-up capital of ₹12.85 Cr. It is led by directors including Anil Satwani (Managing Director) and Pratik Patel.
Its last annual general meeting (AGM) was held on 17 August 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mhow, Madhya Pradesh.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹869.15 Cr, a growth of 15.6% compared to the previous year. For the same year it recorded a net profit of ₹115.31 Cr (net margin 13.3%) and EBITDA of ₹229.66 Cr (EBITDA margin 26.4%). The net worth stands at ₹1,149.73 Cr (up 41.1% YoY). Total assets are valued at ₹1,567.94 Cr (up 14.1% YoY).
The company has about 1,330 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Symbiotec. As per MCA filings, the company has open charges of ₹555.98 Cr and satisfied charges of ₹396.04 Cr on record. Court records list 2 cases involving the company, including 2 filed by the company; 1 case is pending. The company has 17 deals on record (8 secondary share transfers, 5 funding rounds, 1 rights issue), with disclosed funding of ₹165.42 Cr; the latest was in September 2026. Its 8 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Virupaksha Organics Limited with revenue of ₹816.52 Cr. The company has 15 MSME Form 1 returns on record between 2019 and 2024, listing 1,371 overdue payments to 129 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website symbiotec.in.
Company details
CIN history
Symbiotec Pharmalab has one previous CIN (Corporate Identification Number): U24232MP2002PTC015293. The current CIN is U24232MP2002PLC015293, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232MP2002PLC015293 | Current |
| U24232MP2002PTC015293 | Previous |
Contact details
Symbiotec Pharmalab Limited's registered office is in Mhow, Madhya Pradesh.
- Social Media
- Registered Address385/2 Pigdamber, Rau, Mhow, Madhya Pradesh, India – 453331
- IndustryPharma, API Manufacturers
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Symbiotec Pharmalab operates one associated brand: Symbiotec. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Non-sterile steroid hormone-based APIs and intermediates are manufactured. | symbiotec.in |
Business activity
The main business activity of Symbiotec Pharmalab is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Symbiotec Pharmalab Limited, buy the company report.
Financials of Symbiotec Pharmalab Limited
FY 2025-26 filings availableSymbiotec Pharmalab Limited reported revenue of ₹869.15 Cr (up 15.6% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 869 | 752 | 716 | 567 | 682 | 633 |
| Revenue growth | +15.7% | +4.9% | +26.4% | -16.9% | +7.7% | - |
| EBITDA | 230 | 203 | 172 | 69.53 | 131 | 195 |
| EBITDA margin | +26.4% | +27.0% | +24.0% | +12.3% | +19.3% | +30.8% |
| Profit before tax | 153 | 147 | 132 | 39.33 | 105 | 173 |
| Net profit | 115 | 96.97 | 100 | 23.45 | 77.53 | 123 |
| Net profit margin | +13.3% | +12.9% | +14.0% | +4.1% | +11.4% | +19.5% |
| EPS (₹) | 17.52 | 17.70 | 91.49 | 21.48 | 70.89 | 112.73 |
| Balance sheet | ||||||
| Total assets | 1,568 | 1,374 | 976 | 848 | 670 | 574 |
| Net worth | 1,150 | 815 | 715 | 622 | 599 | 521 |
| Total debt | 391 | 544 | 247 | 218 | 64.66 | 47.42 |
| Cash & bank | 10.13 | 26.47 | 7.56 | 5.71 | 10.69 | 48.67 |
| Net working capital | 279 | 309 | 209 | 278 | 301 | 244 |
| Cash flow | ||||||
| Cash from operations | 175 | 47.26 | 188 | 69.24 | 17.71 | 174 |
| Cash from investing | (227) | (307) | (206) | (220) | (31.64) | (96.35) |
| Cash from financing | 35.99 | 278 | 21.85 | 146 | 15.14 | (79.28) |
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 |
|---|---|---|---|
| Revenue | 218 | 245 | 203 |
| Revenue growth (YoY) | +7.4% | - | - |
| Other income | 0.34 | 0.16 | 2.64 |
| EBITDA | 45.20 | 62.09 | 57.96 |
| EBITDA margin | +20.7% | +25.3% | +28.5% |
| Depreciation | 21.82 | 19.75 | 10.51 |
| Interest | 6.18 | 7.26 | 5.28 |
| Profit before tax | 17.54 | 35.24 | 44.81 |
| Tax | 3.47 | 7.71 | 14.90 |
| Net profit | 14.07 | 27.53 | 29.91 |
| EPS (₹) | 2.24 | 4.76 | 5.34 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 845 | 757 | 674 | 564 | 634 | 623 |
| Revenue growth | +11.7% | +12.3% | +19.5% | -11.1% | +1.8% | - |
| EBITDA | 180 | 219 | 143 | 15.52 | 105 | 202 |
| EBITDA margin | +21.2% | +28.9% | +21.2% | +2.8% | +16.6% | +32.5% |
| Profit before tax | 173 | 196 | 118 | (7.78) | 82.77 | 183 |
| Net profit | 156 | 146 | 88.93 | 56.99 | 61.72 | 136 |
| Net profit margin | +18.5% | +19.3% | +13.2% | +10.1% | +9.7% | +21.8% |
| EPS (₹) | 20.03 | 133.35 | 81.33 | (20.72) | 56.45 | 123.96 |
| Balance sheet | ||||||
| Total assets | - | 1,219 | 825 | 787 | 765 | 687 |
| Net worth | - | 911 | 761 | 673 | 695 | 633 |
| Total debt | - | 293 | 51.72 | 107 | 63.59 | 47.42 |
| Cash & bank | - | 22.59 | 6.27 | 2.83 | 6.32 | 41.14 |
| Net working capital | - | 371 | 250 | 278 | 306 | 276 |
| Cash flow | ||||||
| Cash from operations | - | 83.29 | 147 | 93.35 | 23.62 | 158 |
| Cash from investing | - | (292) | (80.80) | (132) | (33.94) | (78.99) |
| Cash from financing | - | 225 | (62.98) | 36.53 | 14.73 | (79.04) |
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 |
|---|---|---|---|
| Revenue | 211 | 213 | 204 |
| Revenue growth (YoY) | +3.2% | - | - |
| Other income | 19.55 | 18.68 | 11.47 |
| Total expenses | 152 | 217 | 142 |
| EBITDA | 59.24 | (3.87) | 62.34 |
| EBITDA margin | +28.1% | -1.8% | +30.5% |
| Depreciation | 10.15 | 11.31 | 9.30 |
| Interest | 5.62 | 6.45 | 5.11 |
| Profit before tax | 63.02 | (2.95) | 59.40 |
| Tax | 16.01 | 12.73 | 14.90 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 |
|---|---|---|---|
| Revenue | 218 | 245 | 203 |
| Revenue growth (YoY) | +7.4% | - | - |
| Other income | 0.34 | 0.16 | 2.64 |
| EBITDA | 45.20 | 62.09 | 57.96 |
| EBITDA margin | +20.7% | +25.3% | +28.5% |
| Depreciation | 21.82 | 19.75 | 10.51 |
| Interest | 6.18 | 7.26 | 5.28 |
| Profit before tax | 17.54 | 35.24 | 44.81 |
| Tax | 3.47 | 7.71 | 14.90 |
| Net profit | 14.07 | 27.53 | 29.91 |
| EPS (₹) | 2.24 | 4.76 | 5.34 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 869 | 752 | 716 | 567 | 682 | 633 |
| Revenue growth | +15.7% | +4.9% | +26.4% | -16.9% | +7.7% | - |
| Other income | 3.11 | 4.43 | 7.09 | 6.46 | 3.00 | 7.03 |
| Total expenses | 639 | 549 | 544 | 497 | 550 | 438 |
| Employee cost | 154 | 122 | 104 | 94.08 | 83.64 | 74.67 |
| EBITDA | 230 | 203 | 172 | 69.53 | 131 | 195 |
| EBITDA margin | +26.4% | +27.0% | +24.0% | +12.3% | +19.3% | +30.8% |
| Depreciation | 53.28 | 43.10 | 38.82 | 28.52 | 25.83 | 22.47 |
| Interest | 26.14 | 16.91 | 7.96 | 8.14 | 3.14 | 6.79 |
| Profit before tax | 153 | 147 | 132 | 39.33 | 105 | 173 |
| Tax | 43.46 | 50.19 | 30.93 | 14.78 | 28.18 | 48.38 |
| Net profit | 115 | 96.97 | 100 | 23.45 | 77.53 | 123 |
| Net profit margin | +13.3% | +12.9% | +14.0% | +4.1% | +11.4% | +19.5% |
| EPS (₹) | 17.52 | 17.70 | 91.49 | 21.48 | 70.89 | 112.73 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 12.55 | 10.94 | 10.94 | 10.94 | 10.94 | 10.94 |
| Reserves & surplus | 1,137 | 804 | 704 | 611 | 588 | 510 |
| Shareholders' funds (net worth) | 1,150 | 815 | 715 | 622 | 599 | 521 |
| Minority interest | (0.14) | (0.19) | (0.21) | (0.09) | (0.11) | 0.04 |
| Secured loans | 388 | 541 | 247 | 218 | 64.66 | 47.42 |
| Unsecured loans | 3.08 | 3.52 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 391 | 544 | 247 | 218 | 64.66 | 47.42 |
| Total liabilities | 1,568 | 1,374 | 976 | 848 | 670 | 574 |
| Assets | ||||||
| Gross block | 1,401 | 668 | 642 | 454 | 407 | 363 |
| Net block | 1,120 | 438 | 448 | 299 | 280 | 261 |
| Capital work in progress | 64.48 | 568 | 208 | 182 | 39.68 | 27.58 |
| Investments | 4.48 | 1.45 | 3.51 | 4.82 | 5.41 | 5.36 |
| Inventories | 237 | 261 | 336 | 244 | 246 | 226 |
| Sundry debtors | 198 | 176 | 126 | 112 | 144 | 118 |
| Cash & bank balances | 10.13 | 26.47 | 7.56 | 5.71 | 10.69 | 48.67 |
| Loans & advances | 40.94 | 29.28 | 39.19 | 38.74 | 25.61 | 30.66 |
| Total current assets | 486 | 493 | 508 | 400 | 425 | 423 |
| Total current liabilities | 207 | 184 | 299 | 122 | 125 | 179 |
| Net working capital | 279 | 309 | 209 | 278 | 301 | 244 |
| Total assets | 1,568 | 1,374 | 976 | 848 | 670 | 574 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 26.39 | 7.50 | 4.55 | 9.16 | 7.96 | 9.25 |
| Net cash from operating activities | 175 | 47.26 | 188 | 69.24 | 17.71 | 174 |
| Net cash from investing activities | (227) | (307) | (206) | (220) | (31.64) | (96.35) |
| Net cash from financing activities | 35.99 | 278 | 21.85 | 146 | 15.14 | (79.28) |
| Net change in cash | (16.35) | 18.90 | 2.94 | (4.61) | 1.21 | (1.30) |
| Closing cash | 10.13 | 26.47 | 7.56 | 5.71 | 10.69 | 48.67 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +15.7% | +4.9% | +26.4% | -16.9% | +7.7% | - |
| EBITDA growth | +13.4% | +17.7% | +147.5% | -47.1% | -32.5% | - |
| PBT growth | +4.3% | +11.1% | +236.5% | -62.7% | -38.9% | +9997.0% |
| Net income growth | +18.9% | -3.1% | +326.7% | -69.8% | -37.1% | - |
| Revenue CAGR (3Y) | +15.3% | +3.3% | +4.2% | - | - | - |
| EBITDA CAGR (3Y) | +48.9% | +15.5% | -4.1% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +12.6% | +12.9% | +14.2% | +4.3% | +11.3% | +19.6% |
| Return on capital employed | +12.2% | +14.0% | +15.4% | +6.3% | +17.5% | +32.7% |
| Return on net worth | +11.2% | +12.7% | +15.2% | +4.0% | +13.8% | +27.1% |
| Debt / equity | 0.48 | 0.52 | 0.35 | 0.23 | 0.10 | 0.18 |
| Long-term debt / equity | 0.17 | 0.29 | 0.23 | 0.09 | 0.00 | 0.00 |
| Interest cover | 14.82 | 10.60 | 5.97 | 19.85 | 2.97 | 3.94 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 0.84 | 1.15 | 1.31 | 1.32 | 1.77 | 1.88 |
| Inventory turnover | 3.49 | 2.52 | 2.47 | 2.31 | 2.89 | 2.77 |
| Debtors turnover | 4.66 | 4.99 | 6.03 | 4.44 | 5.21 | 5.65 |
| EPS (₹) | 17.52 | 17.70 | 91.49 | 21.48 | 70.89 | 112.73 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 183.27 | 149.03 | 653.85 | 568.34 | 547.46 | 475.97 |
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 |
|---|---|---|---|
| Revenue | 211 | 213 | 204 |
| Revenue growth (YoY) | +3.2% | - | - |
| Other income | 19.55 | 18.68 | 11.47 |
| Total expenses | 152 | 217 | 142 |
| EBITDA | 59.24 | (3.87) | 62.34 |
| EBITDA margin | +28.1% | -1.8% | +30.5% |
| Depreciation | 10.15 | 11.31 | 9.30 |
| Interest | 5.62 | 6.45 | 5.11 |
| Profit before tax | 63.02 | (2.95) | 59.40 |
| Tax | 16.01 | 12.73 | 14.90 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 845 | 757 | 674 | 564 | 634 | 623 |
| Revenue growth | +11.7% | +12.3% | +19.5% | -11.1% | +1.8% | - |
| Other income | 56.73 | 32.00 | 19.76 | 12.37 | 5.65 | 9.01 |
| Total expenses | 666 | 538 | 531 | 548 | 529 | 420 |
| Employee cost | 0.00 | 119 | 102 | 92.55 | 81.74 | 72.77 |
| EBITDA | 180 | 219 | 143 | 15.52 | 105 | 202 |
| EBITDA margin | +21.2% | +28.9% | +21.2% | +2.8% | +16.6% | +32.5% |
| Depreciation | 39.37 | 38.36 | 37.26 | 27.62 | 25.11 | 22.18 |
| Interest | 23.80 | 16.65 | 7.54 | 8.05 | 3.07 | 6.52 |
| Profit before tax | 173 | 196 | 118 | (7.78) | 82.77 | 183 |
| Tax | 57.23 | 50.20 | 28.95 | 14.88 | 21.05 | 47.11 |
| Net profit | 156 | 146 | 88.93 | 56.99 | 61.72 | 136 |
| Net profit margin | +18.5% | +19.3% | +13.2% | +10.1% | +9.7% | +21.8% |
| EPS (₹) | 20.03 | 133.35 | 81.33 | (20.72) | 56.45 | 123.96 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | - | 10.94 | 10.94 | 10.94 | 10.94 | 10.94 |
| Reserves & surplus | - | 900 | 750 | 662 | 684 | 622 |
| Shareholders' funds (net worth) | - | 911 | 761 | 673 | 695 | 633 |
| Secured loans | - | 293 | 51.72 | 107 | 63.59 | 47.42 |
| Unsecured loans | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | - | 293 | 51.72 | 107 | 63.59 | 47.42 |
| Total liabilities | - | 1,219 | 825 | 787 | 765 | 687 |
| Assets | ||||||
| Gross block | - | 545 | 514 | 418 | 392 | 349 |
| Net block | - | 317 | 324 | 266 | 266 | 248 |
| Capital work in progress | - | 59.05 | 19.36 | 73.90 | 22.62 | 26.73 |
| Investments | - | 44.20 | 42.25 | 65.60 | 130 | 123 |
| Inventories | - | 254 | 333 | 242 | 245 | 225 |
| Sundry debtors | - | 176 | 125 | 112 | 144 | 119 |
| Cash & bank balances | - | 22.59 | 6.27 | 2.83 | 6.32 | 41.14 |
| Loans & advances | - | 26.63 | 33.98 | 29.76 | 20.24 | 26.94 |
| Total current assets | - | 479 | 498 | 387 | 416 | 412 |
| Total current liabilities | - | 108 | 248 | 108 | 109 | 136 |
| Net working capital | - | 371 | 250 | 278 | 306 | 276 |
| Total assets | - | 1,219 | 825 | 787 | 765 | 687 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | - | 6.20 | 2.53 | 5.15 | 0.74 | 1.07 |
| Net cash from operating activities | - | 83.29 | 147 | 93.35 | 23.62 | 158 |
| Net cash from investing activities | - | (292) | (80.80) | (132) | (33.94) | (78.99) |
| Net cash from financing activities | - | 225 | (62.98) | 36.53 | 14.73 | (79.04) |
| Net change in cash | - | 16.31 | 3.67 | (2.62) | 4.41 | (0.33) |
| Closing cash | - | 22.59 | 6.27 | 2.83 | 6.32 | 41.14 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +11.7% | +12.3% | +19.5% | -11.1% | +1.8% | - |
| EBITDA growth | -18.0% | +53.2% | +820.9% | -85.3% | -48.0% | - |
| PBT growth | -11.7% | +66.3% | +9998.0% | - | -54.7% | +9997.0% |
| Net income growth | +6.9% | +64.0% | +56.0% | -7.7% | -54.5% | - |
| Revenue CAGR (3Y) | +14.5% | +6.1% | +2.7% | - | - | - |
| EBITDA CAGR (3Y) | +126.2% | +27.7% | -10.9% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +13.7% | +19.3% | +13.2% | -4.0% | +9.7% | +21.8% |
| Return on capital employed | - | +20.8% | +15.6% | +8.4% | +11.8% | +28.9% |
| Return on net worth | - | +17.4% | +12.4% | +8.3% | +9.3% | +24.0% |
| Debt / equity | - | 0.21 | 0.11 | 0.12 | 0.08 | 0.15 |
| Long-term debt / equity | - | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 16.98 | 9.22 | 7.14 | -66.53 | 3.83 | 3.62 |
| Efficiency & per share | ||||||
| Fixed asset turnover | - | 1.43 | 1.45 | 1.39 | 1.71 | 1.89 |
| Inventory turnover | - | 2.58 | 2.35 | 2.31 | 2.69 | 2.73 |
| Debtors turnover | - | 5.02 | 5.67 | 4.40 | 4.83 | 5.52 |
| EPS (₹) | 20.03 | 133.35 | 81.33 | (20.72) | 56.45 | 123.96 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 832.83 | 695.99 | 615.23 | 635.68 | 579.15 |
To see the full year-wise statements and ratios of Symbiotec Pharmalab Limited, buy the company report.
Board of directors of Symbiotec Pharmalab Limited
Symbiotec Pharmalab has 6 current directors and 25 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rohit Brijmohan Mantri Also directs: Symbiotec Biologics Private Limited, Symbiotec Zenfold Private Limited, Knovea Pharmaceutical Private Limited and 5 more | Nominee Director | 06 Dec 2018 | 7 Years 10 Months | Current |
| Anil Satwani | Managing Director | 20 Sep 2002 | 24 Years 1 Months | Current |
| Pratik Patel Also directs: Jash Engineering Ltd, Patamin Investments Private Limited, Jash Invent India Private Limited and 2 more | Director | 16 Dec 2025 | 0 Years 10 Months | Current |
| Sunita Kishnani Also directs: Jash Engineering Ltd | Director | 27 Nov 2025 | 0 Years 11 Months | Current |
| Dhananjay Narendra Mungale Also directs: NGL Fine-Chem Limited, Kalpataru Projects International Limited, Lichfl Asset Management Company Limited and 4 more | Nominee Director | 06 Aug 2026 | 0 Years 2 Months | Current |
| Pramod Kasat Also directs: Advanced Enzyme Technologies Limited, Sai Silks (Kalamandir) Limited, Natural Capsules Limited and 5 more | Director | 21 Jul 2026 | 0 Years 3 Months | Current |
Peer comparison
Symbiotec Pharmalab Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Symbiotec Pharmalab Limitedthis company | ₹869.15 Cr (FY 2026) | ₹115.31 Cr | 13.3% | 15.6% | Mhow, Madhya Pradesh, India | |
| Virupaksha Organics Limited | ₹816.52 Cr (FY 2025) | 6.0% | Hyderabad, Telangana, India | |||
| Symed Labs Limited | ₹791.92 Cr (FY 2025) | 6.0% | Hyderabad, Telangana, India | |||
| Sterile India Private Limited | ₹791.14 Cr (FY 2025) | -13.0% | New Delhi, Delhi, India | |||
| SMS Pharmaceuticals Limited | ₹788.97 Cr (FY 2025) | 11.0% | Hyderabad, Telangana, India | |||
| Tagoor Laboratories Private Limited | ₹719.28 Cr (FY 2022) | 55.0% | Andhra Pradesh, India | |||
| Optimus Drugs Private Limited | ₹713.55 Cr (FY 2024) | -41.0% | Hyderabad, Telangana, India | |||
| Supriya Lifescience Limited | ₹706.3 Cr (FY 2025) | 22.0% | Mumbai, Maharashtra, India | |||
| Dasami Lab Private Limited | ₹694.39 Cr (FY 2025) | 22.0% | Chityal, Telangana, India |
To see the full peer comparison of Symbiotec Pharmalab Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 23 Jul 2025 | 101139783 | State Bank of India | ₹25,000 | Open | |
| 27 Sep 2024 | 100986513 | Sbicap Trustee Company Limited | ₹555.98 Cr | Open | |
| 28 Jul 2022 | 100604774 | Axis Bank Limited | ₹1.99 Cr | Satisfied | |
| 06 Feb 2019 | 100243943 | Yes Bank Limited | ₹49 Lakh | Satisfied | |
| 01 Mar 2018 | 100185853 | Hdfc Bank Limited | ₹1.25 Cr | Satisfied |
To see the full charge records of Symbiotec Pharmalab Limited, buy the company report.
Total charge records: 18 View all charges
Deals & funding
Symbiotec Pharmalab Limited has 17 deals on record (8 secondary share transfers, 5 funding rounds, 1 rights issue), with disclosed funding of ₹165.42 Cr; the latest was in September 2026.
Deals on record (5 of 17)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2026 | Market trade | ₹62.68 Cr | Buyer: Irage Broking Services LLP Seller: Irage Broking Services LLP |
| Aug 2026 | IPO | ₹1,757.3 Cr | Investors: Public Market Investors Seller: Satwani Holdings LLP , Rosewood Investments, Motilal Oswal Private Equity |
| Dec 2018 | Funding round | ₹5 Cr | Investors: Satwani Holdings LLP |
| Dec 2018 | Secondary share transfer | Undisclosed | Buyer: InvAscent, Motilal Oswal Private Equity, 2 individuals Seller: Mulji Mehta and Sons Pvt Ltd , 3 individuals |
| Mar 2011 | Secondary share transfer | Undisclosed | Buyer: Mulji Mehta and Sons Pvt Ltd , 3 individuals Seller: Ashok Finstock Limited , 2 individuals |
To see the full deal history of Symbiotec Pharmalab Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Symbiotec Pharmalab Limited has 2 court cases on record: 2 filed by Symbiotec Pharmalab. 1 case is pending and 1 is disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 1 | 0 | 0 |
| NCLT | 1 | 0 | 1 |
Cases on record (2 of 2)
| Court | Type of case | Party | Status |
|---|---|---|---|
| NCLT, NCLT Indore | Company petition | Filed by the company against Registrar of Companies | Pending |
| High Court of Madhya Pradesh | Writ petition | Filed by the company against Union of India | Disposed |
To see the full case history of Symbiotec Pharmalab Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Symbiotec Pharmalab Limited was last rated by Care on 10 Jun 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 10 Jun 2022 |
To see the full credit ratings and regulatory alerts of Symbiotec Pharmalab Limited, buy the company report.
MSME payment delays
Symbiotec Pharmalab Limited has 15 MSME Form 1 returns on record between 2019 and 2024, listing 1,371 overdue payments to 129 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 129)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Accelerate Chemicals Private Limited | |||
| Gorav Polymers Private Limited | |||
| an individual supplier | |||
| Gandhi Automations Private Limited |
To see the full MSME payment records of Symbiotec Pharmalab Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Symbiotec Pharmalab has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 23AAGCS9311M1Z5 | Madhya Pradesh | Active | 01 Jul 2017 |
| 23AAGCS9311M2Z4 | Madhya Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Symbiotec Pharmalab Limited, buy the company report.
Recent activity
Symbiotec Pharmalab Limited has 31 board changes on record since 2002: 6 appointments and 25 cessations. The latest: Dhananjay Narendra Mungale was appointed as Nominee Director on 06 Aug 2026.
60 earlier events are in the company report.
News
Frequently asked questions
Symbiotec Pharmalab is an active public limited company based in Mhow, Madhya Pradesh, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 20 September 2002 (24+ years old) and is registered under CIN U24232MP2002PLC015293. Listed on BSE: 544889 and NSE: SYMBIOTEC.
Symbiotec Pharmalab reported revenue of ₹869.15 Cr for FY 2025-26 (up 15.6% YoY) based on consolidated financials.
Symbiotec Pharmalab has 6 current directors:
- Anil Satwani - Managing Director
- Rohit Brijmohan Mantri - Nominee Director
- Pratik Patel - Director
- Sunita Kishnani - Director
- Dhananjay Narendra Mungale - Nominee Director
- Pramod Kasat - Director
The latest financial statements of Symbiotec Pharmalab on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 17 August 2026. Year-wise statements from 2015 are in the company report.
The GSTIN of Symbiotec Pharmalab is 23AAGCS9311M1Z5, registered in Madhya Pradesh. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 23AAGCS9311M2Z4 (Madhya Pradesh).
The CIN (Corporate Identification Number) of Symbiotec Pharmalab is U24232MP2002PLC015293. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Symbiotec Pharmalab is a listed company as per MCA records. Its shares are listed on both BSE (code: 544889) and NSE (symbol: SYMBIOTEC).
Symbiotec Pharmalab has 2 court cases on record: 2 filed by the company. 1 is pending. Most are in the high courts.
Symbiotec Pharmalab was incorporated on 20 September 2002, making it 24+ years old. It is registered with the Registrar of Companies, Gwalior.
Symbiotec Pharmalab has 17 deals on record (8 secondary share transfers, 5 funding rounds, 1 rights issue), with disclosed funding of ₹165.42 Cr; the latest was in September 2026.
The peers of Symbiotec Pharmalab by revenue are Virupaksha Organics Limited, Symed Labs Limited, Sterile India Private Limited, SMS Pharmaceuticals Limited, Tagoor Laboratories Private Limited and 3 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Dhananjay Narendra Mungale was appointed as Nominee Director on 06 Aug 2026. Pramod Kasat was appointed as Director on 21 Jul 2026. Brij Mohan Maheshwari ceased to be Additional Director on 16 Dec 2025. Symbiotec Pharmalab has 31 board changes on record in total.